Drug Innovation
Commentary
Reforming PBM Practices Would Improve The Pharmacy Market
Patients, the ultimate healthcare arbiter, continue to bear the costs from the perverse incentives driving the pharmacy benefit manager (PBM) market. Because of these disincentives patients pay excessive out-of-pocket costs. Just as troubling, the misaligned incentives create impediments that dictate where patients can fill their prescriptions and which prescriptions they can ...
Commentary
The Federal Trade Commission’s Assault On Growth
The FTC’s mission is to protect consumers by ensuring that markets are competitive, not to protect competitors. Presumably, the Commissioners imagine that the theoretical harm to competitors will somehow make consumers worse off, but if this sounds far-fetched, this is precisely what an FTC administrative judge concluded when hearing the ...
Commentary
Government Regulation Threatens Life-Saving Innovation
Drug Companies Are Delivering a “Golden Age of Medicine.” Let’s Protect It.
New vaccines for scourges like malaria and respiratory syncytial virus, or RSV. New cancer drugs that can cut death rates by half or even cause complete remission. The discovery of a biomarker that could identify people who would benefit from investigational drugs for Parkinson’s Disease. Breakthrough treatments that curb obesity ...
Commentary
Learn how price controls threaten access to drugs
Despite Democrats’ Celebratory Mood, It’s A Sad Day For American Patients.
President Joe Biden celebrated a milestone today—but American patients have no reason to cheer. The White House announced the first 10 prescription drugs that, starting in 2026, will be subject to price controls authorized by the Inflation Reduction Act . . . It’s laudable that lawmakers want to reduce out-of-pocket ...
Commentary
Bipartisan Price Transparency Reforms Will Improve Outcomes
Beneficial healthcare change is occurring – in a bipartisan manner too. The reform, referred to as the Transparency in Coverage (Tic) rule, improves the functioning of the healthcare market; and unlike the calls for price controls or increased government distortions, improving the efficiency of the healthcare market can achieve the ...
Commentary
PBM Industry Shadowy, Congress Shines Much Needed Light
The last few months have seen a flurry of activity on Capitol Hill regarding prescription drug reform, with a particular focus on pharmacy benefit managers, or PBMs. The U.S. Senate Finance Committee is set to markup a bipartisan PBM reform bill within the next few days. The House Energy and Commerce ...
Commentary
Imposing Price Controls Is Never The Answer
The Senate Health, Education, Labor, and Pensions (HELP) Committee is currently reauthorizing the Pandemic and All-Hazards Preparedness Act (PAHPA), which is supposed to help us prepare for the next public health emergency. Never missing an opportunity to impose price controls on anything and everything, Senator Bernie Sanders (I-VT) wants to ...
Commentary
Democrats want to take medicinal price controls further
Senate Democrats Take One More Step Toward Socialized Medicine
It’s been less than a year since Democrats enacted the Inflation Reduction Act, which gives Medicare the power to set the prices of certain medicines. Those price controls have yet to go into effect. But Democrats already want more. They’ve introduced new legislation that would amp up those price controls ...
Commentary
There is a new Senate bill that targets PBMs
Break the Grip of Pharmacy Benefit Managers
A new Senate bill takes aim at one of the chief drivers of the high out-of-pocket drug costs that many consumers are experiencing — middlemen known as “pharmacy benefit managers.” Introduced in mid-June by a bipartisan group of senators including Finance Committee Chair Ron Wyden, D-Ore., and Ranking Member Mike Crapo, R-Idaho, ...
Commentary
Read the latest on drug price controls
Dems’ Drug Price Controls Would Mean Fewer Drugs And Fewer Jobs
Hundreds of lifesaving therapies will never be invented, and as many as 1.1 million jobs will be lost if Senate Democrats successfully expand their prescription drug price-fixing program, according to a major new study. The study, conducted by the research group Vital Transformation, modeled the effects of the SMART Prices Act. Sponsored ...
Reforming PBM Practices Would Improve The Pharmacy Market
Patients, the ultimate healthcare arbiter, continue to bear the costs from the perverse incentives driving the pharmacy benefit manager (PBM) market. Because of these disincentives patients pay excessive out-of-pocket costs. Just as troubling, the misaligned incentives create impediments that dictate where patients can fill their prescriptions and which prescriptions they can ...
The Federal Trade Commission’s Assault On Growth
The FTC’s mission is to protect consumers by ensuring that markets are competitive, not to protect competitors. Presumably, the Commissioners imagine that the theoretical harm to competitors will somehow make consumers worse off, but if this sounds far-fetched, this is precisely what an FTC administrative judge concluded when hearing the ...
Government Regulation Threatens Life-Saving Innovation
Drug Companies Are Delivering a “Golden Age of Medicine.” Let’s Protect It.
New vaccines for scourges like malaria and respiratory syncytial virus, or RSV. New cancer drugs that can cut death rates by half or even cause complete remission. The discovery of a biomarker that could identify people who would benefit from investigational drugs for Parkinson’s Disease. Breakthrough treatments that curb obesity ...
Learn how price controls threaten access to drugs
Despite Democrats’ Celebratory Mood, It’s A Sad Day For American Patients.
President Joe Biden celebrated a milestone today—but American patients have no reason to cheer. The White House announced the first 10 prescription drugs that, starting in 2026, will be subject to price controls authorized by the Inflation Reduction Act . . . It’s laudable that lawmakers want to reduce out-of-pocket ...
Bipartisan Price Transparency Reforms Will Improve Outcomes
Beneficial healthcare change is occurring – in a bipartisan manner too. The reform, referred to as the Transparency in Coverage (Tic) rule, improves the functioning of the healthcare market; and unlike the calls for price controls or increased government distortions, improving the efficiency of the healthcare market can achieve the ...
PBM Industry Shadowy, Congress Shines Much Needed Light
The last few months have seen a flurry of activity on Capitol Hill regarding prescription drug reform, with a particular focus on pharmacy benefit managers, or PBMs. The U.S. Senate Finance Committee is set to markup a bipartisan PBM reform bill within the next few days. The House Energy and Commerce ...
Imposing Price Controls Is Never The Answer
The Senate Health, Education, Labor, and Pensions (HELP) Committee is currently reauthorizing the Pandemic and All-Hazards Preparedness Act (PAHPA), which is supposed to help us prepare for the next public health emergency. Never missing an opportunity to impose price controls on anything and everything, Senator Bernie Sanders (I-VT) wants to ...
Democrats want to take medicinal price controls further
Senate Democrats Take One More Step Toward Socialized Medicine
It’s been less than a year since Democrats enacted the Inflation Reduction Act, which gives Medicare the power to set the prices of certain medicines. Those price controls have yet to go into effect. But Democrats already want more. They’ve introduced new legislation that would amp up those price controls ...
There is a new Senate bill that targets PBMs
Break the Grip of Pharmacy Benefit Managers
A new Senate bill takes aim at one of the chief drivers of the high out-of-pocket drug costs that many consumers are experiencing — middlemen known as “pharmacy benefit managers.” Introduced in mid-June by a bipartisan group of senators including Finance Committee Chair Ron Wyden, D-Ore., and Ranking Member Mike Crapo, R-Idaho, ...
Read the latest on drug price controls
Dems’ Drug Price Controls Would Mean Fewer Drugs And Fewer Jobs
Hundreds of lifesaving therapies will never be invented, and as many as 1.1 million jobs will be lost if Senate Democrats successfully expand their prescription drug price-fixing program, according to a major new study. The study, conducted by the research group Vital Transformation, modeled the effects of the SMART Prices Act. Sponsored ...
